○Ezgi Ozdemir1, Ryo Yamasaki1, Satoshi Nagata1, Hiroo Yamaguchi1, Yuko Nakamuta1, Katsuhisa Masaki1, Jun-ichi Kira2 (1.Kyushu University, Japan, 2.International University of Health and Welfare)
Session information
Oral Session
[O-03] Oral Session 03 Neuroimmunology1
Wed. May 19, 2021 4:30 PM - 6:00 PM Room 06 (ICC Kyoto 2F Room B-2)
Chair:Yamamura Takashi(National Institute of Neuroscience, NCNP),Okamoto Tomoko(National Center of Neurology and Psychiatry)
○Fumitaka Shimizu1, Ryo Ogawa2, Toshiyuki Takahashi2, Yukio Takeshita1, Tatsuro Misu2, Yasuteru Sano1, Toshihiko Maeda1, Ichiro Nakashima3, Kazuo Fujihara4, Takashi Kanda1 (1.Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan, 2.Department of Neurology, Tohoku University Graduate School of Medicine, 3.Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 4.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University)
○Satoshi Nagata1, Ryo Yamasaki1, Yuko Nakamuta1, Ezgi Ozdemir1, Hiroo Yamaguchi1, Katsuhisa Masaki1, Jun-ichi Kira2,3 (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, 3.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital)
○Yuki Matsumoto1, Kimihiko Kaneko2, Tatsuro Misu1, Chihiro Namatame1, Yoshiki Takai1, Shuhei Nishiyama1, Hiroshi Kuroda1, Toshiyuki Takahashi3, Kazuo Fujihara4,5, Masashi Aoki1 (1.Tohoku University Graduate School of Medicine, Department of Neurology, Sendai, Japan, 2.Japanese Red Cross Ishinomaki Hospital, Department of Neurology, Ishinomaki, Miyagi, Japan, 3.National Hospital Organization Yonezawa Hospital, Department of Neurology, Yonezawa, Yamagata, Japan, 4.Fukushima Medical University, Department of Multiple Sclerosis Therapeutics, 5.Southern Tohoku Research Institute for Neuroscience, Multiple Sclerosis & Neuromyelitis Optica Center, Fukushima, Japan.)
○Ryusei Nishigori1,2, Mio Hamatani2,3, Shinji Ashida4, Masaki Takata1,2, Chihiro Fujii4, Kazuyuki Kawamura5, Hirofumi Ochi6, Ryosuke Takahashi1, Hideki Ueno2, Takayuki Kondou3 (1.Department of Neurology, Graduate School of Medicine, Kyoto University, Japan, 2.Department of Immunology, Graduate School of Medicine, Kyoto University, Japan, 3.Department of Neurology, Medical Center, Kansai Medical University, 4.Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, 5.Department of Neurology, Minami Kyoto Hospital, 6.Department of Neurology, Graduate School of Medicine, Ehime University)
○Mitsuru Watanabe1, David Leppert2, Noriko Isobe1, Takuya Matsushita1, Aleksandra Maceski2, Dimitri Rey2, Sandra Mitrovic3, Yuri Nakamurar1,4,5, Katsuhisa Masaki1, Jun-ichi Kira1,4,6, Jens Kuhle2 (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, 3.Laboratory Medicine, University Hospital Basel, University of Basel, 4.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 5.School of Pharmacy at Fukuoka, International University of Health and Welfare, 6.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare)